DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for pigment dispersion syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePigment dispersion syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pigment dispersion syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
glutamate metabotropic receptor 5 (GRM5) — GRM5 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8TAO · 2.9 Å · ligand (S)-2-AMINO-3-(3,5-DIOXO-[1,2,4]OXADIAZOLIDIN-2-YL)-PROPIONIC ACID (QUS). Experimental structure, not a prediction.
What the evidence adds up to
Thirteen patients with asymmetric pigment dispersion syndrome showed no difference in lens thickness, refractive error, or axial length between more and less affected eyes. The more affected eye had greater iris concavity, greater iris-lens contact distance, and a greater distance from the scleral spur to the iris insertion (0.42 mm versus 0.29 mm). A more posterior iris insertion predisposes to the phenotypic expression of the syndrome.
A 45-year-old patient treated with atropine 1% ointment since infancy for bilateral congenital cataracts developed pigment dispersion syndrome with secondary ocular hypertension. This is the second case report linking chronic topical atropine use to pigment dispersion. The patient showed good pressure response to topical prostaglandin therapy. The authors raise the possibility that pigment dispersion is a potential side effect of the drug.
Histopathology has documented anterior and posterior segment involvement by dispersed pigments, including scleral and vitreous pigmentation not previously reported. Retinal pigment degeneration and granule dispersion were seen throughout the retina, which could be a contributing factor in the aetiology. Pigment dispersion syndrome mostly affects young men with myopic refraction and is characterised by Krukenberg spindle, peripheral iris defects, trabecular meshwork pigmentation, and convex iris configuration. Over time it can progress to pigmentary glaucoma and permanent vision loss.
A 2025 review argues that the evidence strongly supports the secondary nature of pigmentary glaucoma and calls for revised classification schemes. What is still missing is prospective data on whether identifying the posterior iris insertion or avoiding drugs like atropine can alter the risk of progression to glaucoma, and whether any intervention beyond standard intraocular pressure lowering changes the natural history. No trial has tested a preventive strategy in an at-risk population.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Ophthalmology · 2006 · 42 citations
Ultrasound Biomicroscopy in Asymmetric Pigment Dispersion Syndrome and Pigmentary Glaucoma
AbstractOBJECTIVE: To identify differences in anterior chamber anatomy among patients with asymmetric pigment dispersion syndrome and no other discernible cause for the asymmetry. METHODS: Ultrasound biomicroscopy and A-scan biometry were performed on both eyes of 13 patients with asymmetric pigment dispersion syndrome without a known cause for asymmetric involvement. A radial perpendicular image in the horizontal temporal meridian detailing the scleral spur, angle anatomy, and iris configuration was obtained for each eye by 2 examiners. RESULTS: There were no differences in lens thickness (P = .33), refractive error (P = .84), or axial length (P = .99) between more and less affected eyes. However, the mean +/- SD iris concavity (P<.001), iris-lens contact distance (P = .02), and distance from the scleral spur to the iris insertion (0.42 +/- 0.11 vs 0.29 +/- 0.06 mm) (P = .002) were greater in the more affected eye of each patient. CONCLUSION: A more posterior iris insertion predisposes to the phenotypic expression of pigment dispersion syndrome.
Journal of Glaucoma · 2017 · 5 citations · open access
A Case of Bilateral Pigment Dispersion Syndrome Following Many Years of Uninterrupted Treatment With Atropine 1% for Bilateral Congenital Cataracts
AbstractPURPOSE: Describe an unusual case of bilateral pigment dispersion syndrome (PDS) following years of uninterrupted treatment with atropine 1% for bilateral congenital cataracts, speculate on potential mechanisms leading to this condition. DESIGN: This is a case report. CASE: A 45-year-old white patient on long-term treatment with atropine 1% ointment since his infancy for bilateral congenital cataracts developed PDS with secondary ocular hypertension. RESULTS: The patient showed all the hallmarks of PDS with secondary ocular hypertension. An anterior segment Swept-Source optical coherence tomography was obtained to review the iris profile. The patient showed good pressure response to topical prostaglandin therapy. CONCLUSIONS: This is the second case report of PDS in a patient with chronic use of topical atropine. The proposed mechanisms for pigment dispersion are discussed and the possibility raised of dispersion being a potential side effect of the drug.
Oman Journal of Ophthalmology · 2023 · 2 citations · open access
Histopathology of Pigment dispersion syndrome and glaucoma
AbstractPigment dispersion syndrome (PDS) can have varied manifestations. Anterior and posterior segment involvement by dispersed pigments was documented in gross pathology and by staining under microscopy. Pigmentary changes in the sclera, cornea, anterior chamber, iris, trabecular meshwork, lens, and retinal pigment epithelium and optic nerve findings were consistent with PDS. External scleral and vitreous pigmentation has never been reported before in the scientific literature. Retinal pigment degeneration and granule dispersion were seen throughout the retina which could be a contributing factor in the etiology of PDS.
Russian Annals of Ophthalmology · 2021 · 2 citations
Pigmentary glaucoma: yesterday, today, tomorrow
AbstractPigment dispersion syndrome (PDS) is a condition that mostly affects young men with myopic refraction. PDS is characterized by the presence of Krukenberg spindle, peripheral iris defects, significant trabecular meshwork pigmentation, as well as convex iris configuration. Such configuration can cause friction of iris's posterior pigment layer on its ligaments, which leads to the release of pigment and its accumulation mostly in the structures of the anterior chamber. Over time PDS can progress into pigmentary glaucoma (PG), which in turn can lead to permanent loss of vision. This review analyzes available data on diagnosis and treatment of PDS and PG.
National Journal glaucoma · 2025 · 0 citations · open access
On the classification of pigmentary glaucoma
AbstractIn this article, the authors attempt to answer the question of which classification form (primary or secondary open-angle) should be assigned to pigmentary glaucoma, which is a clinical stage that completes the progressive course of pigment dispersion syndrome (PDS). The article presents risk factors, pathogenetic mechanisms, and clinical manifestations of PDS at successive stages of its development and briefly discusses the issue of pigmentary glaucoma prevention. Based on literature data and the authors’ own research, the evidence strongly supports the secondary nature of pigmentary glaucoma and the need to revise current classification schemes.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
